Form 8-K ATAI Life Sciences N.V. For: Aug 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
atai Life Sciences N.V (ATAI) PT Lowered to $5 at Jefferies
August 13, 2024 4:04 PM EDTJefferies analyst Andrew Tsai lowered the price target on atai Life Sciences N.V (NASDAQ: ATAI) to $5.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "ATAI's pipeline of psychedelics (and non-psychedelics) has pot'l to safely, profoundly, and durably treat tough $1B+... More
